Search Results
Your search for Matthew S matches 1044 pages
Showing 151 - 200Sitagliptin Added to Tacrolimus/Sirolimus Prophylaxis Regimen for Acute Graft-vs-Host Disease After HSCT
In a phase II trial reported in The New England Journal of Medicine, Sherif S. Farag, MD, PhD, of Indiana University School of Medicine, and colleagues found that the addition of the dipeptidyl peptidase 4 (DPP-4; CD26) inhibitor sitagliptin to tacrolimus and sirolimus prophylaxis resulted in a low ...
Alpelisib Plus Fulvestrant in PIK3CA-Mutant, Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer After Disease Progression
As reported in The Lancet Oncology by Hope S. Rugo, MD, and colleagues, findings in one cohort of the phase II BYLieve trial indicated activity of the PI3Kα-selective inhibitor and degrader alpelisib plus fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced ...
Pembrolizumab in First-Line Treatment of Metastatic Clear Cell and Non–Clear Cell Renal Cell Carcinoma
The treatment paradigm for patients with metastatic renal cell carcinoma has undergone a dramatic shift over the past few years, improving outcomes for many patients but leaving many unanswered questions as to how to optimally choose the best treatment for an individual patient. The changes are...
Effect of Gamification With Social Incentives on Increased Mobility After Hospital Discharge
In a single-institution study reported in JAMA Network Open, Greysen et al found that a strategy of behaviorally designed gamification with social support did not increase mobility among patients discharged from inpatient general medicine or oncology units, although benefit was observed in a...
WEE1 Inhibition in Patients With Recurrent Uterine Serous Carcinoma
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Joyce F. Liu, MD, MPH, and colleagues found that the WEE1 inhibitor adavosertib produced durable responses in women with recurrent uterine serous carcinoma. The investigators stated, “Uterine serous carcinoma is a...
Association of Cardiovascular Risk Factors With Risk of Subsequent Cancer
In a study reported in JACC: CardioOncology, Emily S. Lau, MD, and colleagues found that the presence of cardiovascular disease risk factors was significantly associated with an increased risk of future cancer, although no increased risk was observed among individuals who had a history of...
ROBUST Trial: Addition of Lenalidomide to R-CHOP in Previously Untreated ABC-Type DLBCL
As reported in the Journal of Clinical Oncology by Grzegorz S. Nowakowski, MD, and colleagues, the phase III ROBUST trial showed that the addition of lenalidomide to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP) did not significantly improve...
Once-Weekly Selinexor Plus Bortezomib/Dexamethasone vs Twice-Weekly Bortezomib/Dexamethasone in Multiple Myeloma
As reported in The Lancet by Sebastian Grosicki, MD, of the Medical University of Silesia, Katowice, Poland, and colleagues, the phase III BOSTON trial has shown significantly prolonged progression-free survival with once-weekly selinexor plus bortezomib/dexamethasone vs twice-weekly...
Eprenetapopt Plus Azacitidine in TP53-Mutated MDS and AML
In a Groupe Francophone des Myélodysplasies phase II study reported in the Journal of Clinical Oncology, Cluzeau et al found that the combination of eprenetapopt and azacitidine produced high response rates in previously untreated patients with high-risk TP53-mutated myelodysplastic syndromes (MDS) ...
LuPSMA Leads to Improved PSA Response, Fewer Severe Adverse Events Than Cabazitaxel in Patients With Metastatic Prostate Cancer
In the Australian phase II trial TheraP reported in The Lancet, Michael S. Hofman, FRACP, MBBS, and colleagues found that Lutetium-177–labeled PSMA-617 (LuPSMA) treatment was associated with a higher prostate-specific antigen (PSA) response rate and fewer severe adverse events vs cabazitaxel in...
The CARG-BC Score: Novel Tool for Predicting Chemotherapy Toxicity in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology, Allison Magnuson, DO, of the University of Rochester Medical Center & Wilmot Cancer Institute, and Mina S. Sedrak, MD, MS, of the City of Hope National Medical Center, along with colleagues, have developed a novel risk tool—the Cancer and Aging...
Addition of Lenalidomide to R-CHOP in Newly Diagnosed Patients With DLBCL
In a phase II signal-seeking trial (ECOG-ACRIN E1412) reported in the Journal of Clinical Oncology, Grzegorz S. Nowakowski, MD, and colleagues found that the addition of lenalidomide (R) to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2CHOP) improved outcomes...
Sitagliptin Added to Tacrolimus/Sirolimus Prophylaxis Regimen for Acute Graft-vs-Host Disease After HSCT
In a phase II trial reported in The New England Journal of Medicine, Sherif S. Farag, MD, PhD, of Indiana University School of Medicine, and colleagues, found that the addition of the dipeptidyl peptidase 4 (DPP-4; CD26) inhibitor sitagliptin to tacrolimus and sirolimus prophylaxis resulted in a...
Addition of Sitagliptin to Prophylaxis for Acute Graft-vs-Host Disease
In a phase II trial reported in The New England Journal of Medicine, Sherif S. Farag, MD, PhD, and colleagues found that the addition of the dipeptidyl peptidase 4 (DPP-4; CD26) inhibitor sitagliptin to tacrolimus and sirolimus prophylaxis resulted in a low rate of acute graft-vs-host disease...
Reduced-Dose Intensity-Modulated Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma
In the phase II NRG Oncology HN002 trial reported in the Journal of Clinical Oncology, Sue S. Yom, MD, PhD, and colleagues found that a reduced-dose intensity-modulated radiation therapy (IMRT) regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma satisfied...
Margetuximab-cmkb vs Trastuzumab in Heavily Pretreated Patients With HER2-Positive Breast Cancer: SOPHIA Trial
As reported in JAMA Oncology by Hope S. Rugo, MD, and colleagues, the phase III SOPHIA trial has shown significantly prolonged progression-free survival with margetuximab-cmkb plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive breast cancer who experienced disease...
Addition of Abatacept to Acute Graft-vs-Host Disease Prophylaxis
In a phase II trial (ABA2) reported in the Journal of Clinical Oncology, Watkins et al found that the addition of T-cell costimulation blockade with abatacept to calcineurin inhibitor (CNI)/methotrexate (MTX)–based graft-vs-host disease prophylaxis resulted in reduced rates of acute graft-vs-host...
AAAS Announces Leading Scientists Elected as 2020 Fellows
Nearly 500 members of the American Association for the Advancement of Science (AAAS) have earned the lifetime distinction of AAAS Fellow. The Fellows are elected each year by their peers serving on the Council of AAAS, the organization’s member-run governing body. The title recognizes important...
Selinexor in Relapsed or Refractory Multiple Myeloma
On December 18, 2020, selinexor was approved for use in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma who have received at least one prior therapy.1,2 Selinexor received accelerated approval in 2019 for use in combination with dexamethasone for...
Risk of Atrial Fibrillation and Associated Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
In a single-institution study reported in the Journal of Clinical Oncology, Chang et al found that atrial fibrillation occurs in a substantial proportion of patients who have undergone allogeneic hematopoietic cell transplantation (HCT) and is associated with poor outcomes. Study Details The...
Analysis of Cardiac Data Among Patients Treated With Osimertinib
As reported in the Journal of Clinical Oncology by Michael S. Ewer, MD, JD, PhD, and colleagues, an analysis of data from clinical trials of osimertinib suggests the absence of a “causal relationship” between osimertinib and cardiac failure. Study Details The study involved a post hoc assessment of ...
Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer
Surgery, in addition to treatments like chemotherapy and radiation therapy, may improve survival for certain patients with metastatic breast cancer. A research team studied nearly 13,000 patients with stage IV disease and found that those who had surgery in addition to other treatments had a...
Meta-analysis Shows Superior Disease-Free and Overall Survival With Measurable Residual Disease Negativity in AML
In a systematic review and meta-analysis reported in JAMA Oncology, Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, found that measurable residual disease (MRD) negativity is associated with superior disease-free and overall survival in patients with...
Matthew S. Davids, MD, on CLL/SLL: New Data on Ibrutinib, Venetoclax, and Rituximab Therapies
Matthew S. Davids, MD, of Dana-Farber Cancer Institute, summarizes three key studies from a session he co-moderated on ibrutinib plus venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), long-term responses to these agents for ...
First-Line Atezolizumab Improves Overall Survival vs Chemotherapy in Certain Patients With Metastatic NSCLC
As reported in The New England Journal of Medicine by Roy S. Herbst, MD, PhD, of Yale School of Medicine, and colleagues, the phase III IMpower110 trial has shown significantly prolonged overall survival with first-line atezolizumab vs platinum-based chemotherapy in metastatic non–small cell lung...
No Biochemical Progression-Free Survival Benefit With Adjuvant vs Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer
As reported in The Lancet by Christopher C. Parker, MD, of Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, and colleagues, initial findings in the phase III RADICALS-RT trial have shown no biochemical progression-free survival benefit with adjuvant radiotherapy vs a policy of salvage...
Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Pelster et al found that nivolumab plus ipilimumab produced durable responses and improved survival outcomes in patients with metastatic uveal melanoma. Study Details The trial enrolled 35 patients at The...
Effect of ASH Choosing Wisely Recommendations on Frequency of Surveillance Imaging in Patients With DLBCL
In a retrospective analysis reported in JCO Oncology Practice, Durani et al found that use of surveillance imaging in patients with diffuse large B-cell lymphoma (DLBCL) decreased following publication of the American Society of Hematology (ASH) Choosing Wisely recommendations to limit such imaging ...
Activity of the KRAS G12C Inhibitor Sotorasib in KRAS G12C–Mutant Advanced Solid Tumors
As reported inThe New England Journal of Medicine by David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, a phase I trial (CodeBreak 100) has shown activity of the oral KRAS G12C inhibitor sotorasib in heavily pretreated patients with KRAS G12C–mutant...
Biochemical Progression-Free Survival With Adjuvant vs Salvage Radiotherapy After Radical Prostatectomy: RADICALS-RT Trial
As reported in The Lancet by Christopher C. Parker, MD, and colleagues, initial findings in the phase III RADICALS-RT trial have shown no biochemical progression-free survival benefit and no difference in freedom from nonprotocol hormone therapy with adjuvant radiotherapy vs salvage radiotherapy...
Nab-paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer
In a phase II trial reported in JAMA Oncology, Srikala S. Sridhar, MD, MSc, FRCPC, and colleagues found no difference in progression-free survival with nab-paclitaxel vs paclitaxel in patients with platinum-refractory metastatic urothelial cancer. Study Details In the investigator-initiated...
First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110
As reported in The New England Journal of Medicine by Roy S. Herbst, MD, PhD, and colleagues, the phase III IMpower110 trial has shown significantly prolonged overall survival with first-line atezolizumab vs platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC)...
Long-Term Impact of ADT in Favorable vs Unfavorable Intermediate-Risk Prostate Cancer
In an analysis of long-term data from NRG Oncology’s RTOG 9408 trial reported in JAMA Network Open, Zumsteg et al found that patients with favorable vs unfavorable intermediate-risk prostate cancer had improved overall survival, and that androgen-deprivation therapy (ADT) vs no ADT was associated...
Activity of the KRAS G12C Inhibitor Sotorasib in KRAS p.G12C–Mutant Advanced Solid Tumors
As reported in The New England Journal of Medicine by David S. Hong, MD, and colleagues, the phase I CodeBreaK100 trial showed activity of the oral KRAS G12C inhibitor sotorasib in heavily pretreated patients with KRAS p.G12C–mutant advanced non–small cell lung cancer (NSCLC), colorectal cancer,...
Benefit of Pembrolizumab in High-Risk Stage III Melanoma: 3-Year Follow-up
As reported in the Journal of Clinical Oncology by Alexander M.M. Eggermont, MD, PhD, and colleagues, adjuvant pembrolizumab maintained a significant recurrence-free survival benefit vs placebo in patients with high-risk stage III melanoma after a median 3-year follow-up in the phase III EORTC...
Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphomas
In the TRANSCEND NHL 001 study reported in The Lancet, Jeremy S. Abramson, MD, and colleagues found that the autologous CD19-directed chimeric antigen receptor (CAR) T-cell agent lisocabtagene maraleucel (liso-cel) produced a high response rate in patients with relapsed or refractory large B-cell...
Addition of ATR Inhibitor Berzosertib to Gemcitabine Improves Progression-Free Survival in Recurrent Platinum-Resistant High-Grade Serous Ovarian Cancer
As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, Dana-Farber Cancer Institute, and colleagues, a U.S. Experimental Therapeutics Clinical Trials Network phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia...
Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the antibody-drug conjugate belantamab mafodotin-blmf was granted accelerated approval for treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, ...
Chemotherapy and COVID-19 Outcomes in Patients With Cancer at Memorial Sloan Kettering Cancer Center
In a single-institution study reported in the Journal of Clinical Oncology, Jee et al found that the receipt of cytotoxic chemotherapy within 35 days of COVID-19 diagnosis in patients with cancer was not associated with increased risk of severe or critical COVID-19. The investigators also...
Repurposing Drugs for the Treatment of COVID-19
A vaccine for COVID-19 is currently the Holy Grail, but even if an effective vaccine were developed on a fast-track timetable, it may be effective in only a percentage of people, judging by existing flu vaccines, which show efficacy rates of approximately 45% and vary year by year. Until we have a...
First-Line Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
In a phase Ib trial reported in the Journal of Clinical Oncology, Richard S. Finn, MD, and colleagues found that the combination of lenvatinib and pembrolizumab produced durable responses in patients with unresectable hepatocellular carcinoma who had received no prior systemic chemotherapy. As...
First-Line S-1 Plus Leucovorin and Oxaliplatin vs S-1 Plus Cisplatin in Advanced Gastric Cancer
As reported in The Lancet Oncology by Kang et al, the Japanese-Korean phase III SOLAR trial showed that oral tegafur/gimeracil/oteracil, a combination known as S-1, plus leucovorin and oxaliplatin was associated with a modest but significant improvement in overall survival vs S-1 plus cisplatin in...
Effect of Medicaid Expansion on Breast Cancer Stage at Diagnosis
In a study reported in JAMA Surgery, Le Blanc et al found that Medicaid expansion under the Affordable Care Act was associated with increased insurance coverage and reduction in rates of diagnosis of breast cancer at later stages. Study Details The study involved data from the National Cancer...
Potential Association of Impaired Spermatogenesis and Immune Checkpoint Inhibitor Therapy in Patients With Metastatic Melanoma
In a study reported as a research letter in JAMA Oncology, Scovell et al identified a potential association between the use of immune checkpoint inhibitors and impaired spermatogenesis using autopsy tissue findings in men with a history of metastatic melanoma. Study Details The study involved...
Prolonged Overall Survival With Autologous-Allogeneic vs Tandem Autologous Transplant in Newly Diagnosed Myeloma
In a pooled analysis reported in Bone Marrow Transplantation,1 Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, and colleagues found that autologous hematopoietic cell transplantation followed by reduced-intensity conditioning allogeneic transplantation (auto-allo) was...
Atezolizumab Plus Bevacizumab for Unresectable or Metastatic Hepatocellular Carcinoma
On May 29, 2020, atezolizumab in combination with bevacizumab was approved for treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.1-3 Supporting Efficacy Data Approval was based on findings in the international, open-label,...
IMbrave150 Trial: Atezolizumab Plus Bevacizumab Improves Survival in Unresectable Hepatocellular Carcinoma
As reported in The New England Journal of Medicine by Richard S. Finn, MD, of Jonsson Comprehensive Cancer Center, Geffen School of Medicine at the University of California, Los Angeles, and colleagues, the phase III IMbrave150 trial has shown that anti–programmed cell death ligand 1 (PD-L1) plus...
Ripretinib in Previously Treated Advanced Gastrointestinal Stromal Tumor
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 15, 2020, the receptor tyrosine kinase inhibitor...
Olaparib Plus Bevacizumab in Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, olaparib was granted an expanded indication to include use in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line...
Sources for Better GVHD-Free Relapse-Free Survival After Adult Alternative Donor HCT
In a retrospective study of registry data reported in the Journal of Clinical Oncology, Mehta et al identified alternative donor sources for hematopoietic cell transplantation (HCT) that were associated with better graft-vs-host disease (GVHD)-free (GRFS) and chronic GVHD–free (CRFS) relapse-free...
